Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  SGS    SGSN   CH0002497458

SGS (SGSN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

SGS : Expands and Increases Capacity by 50% at its Lincolnshire, IL Facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/08/2017 | 03:45pm CEST

SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, is expanding its facility in Lincolnshire, in the northern suburbs of Chicago, Illinois.

The expansion will increase the site's current footprint from 38,500 sq. ft. to nearly 58,000 sq. ft. and is due to be completed by September 2017.

The expansion will allow the facility to increase capacity for the wide range of services that it offers, including analytical method development and testing, microbiological evaluation, drug stability studies, testing of containers and medical devices, and utilities qualification and monitoring. Additional staff will be employed to meet the demands on the laboratory.

'This investment allows us to be flexible in our approach to meeting both existing and future customer demands,' commented James Nokes, Vice President, U.S. Agriculture, Food and Life. 'Analysis and bioanalysis techniques continue to evolve rapidly, and are driven by technological advances and regulatory needs. At SGS, it is our aim to ensure we can offer our clients integrated solutions to support their needs, so we continue to invest in capabilities, capacity and our staff to maintain our professionalism and efficiency.'

The expansion at SGS's Lincolnshire site follows a series of recent investments at the company's global laboratory network. Increases in extractables and leachables capabilities have taken place at Fairfield, NJ and Shanghai, China; while French facilities at Poitiers and Villeneuve-la-Garenne have seen investment in bioanalytical capabilities and elemental analysis respectively.

With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.

For further information, please contact:

Jessica Martin
Global Head of Marketing, Life Sciences
SGS
t: +1 847 821 8900
www.sgs.com/lifescience

Richard Kerns
President
NEPR
t: +44 (0)161 728 5880

About SGS

SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 90,000 employees, SGS operates a network of over 2,000 offices and laboratories around the world.

SGS SA published this content on 08 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 08 August 2017 13:44:09 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SGS
07/17SGS : TM 0012 Approved – Measuring Ballast Tank Corrosion from Ballast Wat..
PU
07/17SGS : Testing and Inspection Services for George at ASDA
PU
07/16SGS : CFIA Publishes its Final Safe Food for Canadians Regulations
PU
07/13SGS SA : half-yearly earnings release
07/12NEW AMENDMENT TO EU TOY STANDARD EN : 2014+a1:2018
PU
07/12SGS : Canada Releases New Cosmetic Ingredient Hotlist
PU
07/12SGS : EU Authorizes MBBT (Nano) as a UV Filter in Cosmetic Products
PU
07/10SGS : Teams Up with Baker Hughes, a GE Company, to Launch PCM Solution
PU
07/09SGS : Create Safe Cosmetic Products with SGS’s Innovative Endocrine Disrup..
PU
07/09SGS : Netherlands Laboratory for Consumer Goods
PU
More news
News from SeekingAlpha
06/11SGS acquires Advanced Metrology Solutions 
01/23SGS SA ADR 2017 Q4 - Results - Earnings Call Slides 
2017SGS (SGSOY) Investor Presentation - Slideshow 
2016HEWL : A Legendary Investment 
Financials ( CHF)
Sales 2018 6 740 M
EBIT 2018 1 048 M
Net income 2018 702 M
Debt 2018 663 M
Yield 2018 2,94%
P/E ratio 2018 28,39
P/E ratio 2019 25,91
EV / Sales 2018 3,11x
EV / Sales 2019 2,92x
Capitalization 20 271 M
Chart SGS
Duration : Period :
SGS Technical Analysis Chart | SGSN | CH0002497458 | 4-Traders
Technical analysis trends SGS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 2 539  CHF
Spread / Average Target -3,7%
EPS Revisions
Managers
NameTitle
Frankie Ng Chief Executive Officer
Sergio Marchionne Chairman
Carla D. F. de Geyseleer Chief Financial Officer & Senior Vice President
August François von Finck Director
Shelby R. du Pasquier Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SGS2.91%20 342
FISERV17.24%31 711
WORLDPAY INC7.04%27 039
WIRECARD65.36%21 998
CINTAS CORPORATION23.53%20 886
FIRST DATA CORP34.95%20 726